难治性-话题@MedSci

#难治性#

683篇内容 | 2680人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528842, encodeId=f9ac1528842b1, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=THER ADV GASTROENTER：乌司奴单抗对难治性克罗恩病患者的疗效分析, objectType=article, longId=299690, objectId=88f0299690d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88f0299690d0, replyNumber=0, likeNumber=89, createdTime=2022-02-28, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88f0299690d0, moduleTitle=THER ADV GASTROENTER：乌司奴单抗对难治性克罗恩病患者的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88f0299690d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528841, encodeId=af101528841d8, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, objectType=article, longId=299624, objectId=273529962455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=273529962455, replyNumber=0, likeNumber=94, createdTime=2022-02-26, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=273529962455, moduleTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=273529962455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528840, encodeId=cb881528840af, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, objectType=article, longId=299190, objectId=b29229919036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29229919036, replyNumber=0, likeNumber=81, createdTime=2022-02-21, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29229919036, moduleTitle=JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29229919036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528839, encodeId=0cd1152883993, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=62, createdTime=2022-02-20, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528838, encodeId=7750152883850, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, objectType=article, longId=295762, objectId=3cdc295e62fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cdc295e62fa, replyNumber=0, likeNumber=0, createdTime=2022-02-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cdc295e62fa, moduleTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cdc295e62fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528837, encodeId=8632152883e7b, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, objectType=article, longId=295593, objectId=ab9629559335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9629559335, replyNumber=0, likeNumber=108, createdTime=2022-02-15, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9629559335, moduleTitle=Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9629559335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528836, encodeId=6dd9152883668, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果, objectType=article, longId=295313, objectId=f5062953135a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5062953135a, replyNumber=0, likeNumber=78, createdTime=2022-02-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5062953135a, moduleTitle=AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5062953135a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528835, encodeId=203a152883584, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, objectType=article, longId=295220, objectId=fab329522003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fab329522003, replyNumber=0, likeNumber=73, createdTime=2022-02-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fab329522003, moduleTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab329522003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Neurology：综合多研究，MRI诊断局灶性皮质发育不良难治性癫痫术后优良预后率达70%, objectType=article, longId=294105, objectId=854229410565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854229410565, replyNumber=0, likeNumber=87, createdTime=2022-01-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854229410565, moduleTitle=Neurology：综合多研究，MRI诊断局灶性皮质发育不良难治性癫痫术后优良预后率达70%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=854229410565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528834, encodeId=130b1528834f9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, objectType=article, longId=294099, objectId=a0a42940993e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0a42940993e, replyNumber=0, likeNumber=91, createdTime=2022-01-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0a42940993e, moduleTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0a42940993e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528832, encodeId=60b31528832fe, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Dermatol：阿普利司特可有效治疗难治性和复发性皮肌炎相关皮损, objectType=article, longId=294064, objectId=055d29406471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=055d29406471, replyNumber=0, likeNumber=82, createdTime=2022-01-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=055d29406471, moduleTitle=J Dermatol：阿普利司特可有效治疗难治性和复发性皮肌炎相关皮损, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=055d29406471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528831, encodeId=7bd8152883170, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症, objectType=article, longId=293385, objectId=f20f29338534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f20f29338534, replyNumber=0, likeNumber=69, createdTime=2022-01-05, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f20f29338534, moduleTitle=Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f20f29338534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528830, encodeId=6d4f15288302f, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, objectType=article, longId=293110, objectId=00a32931103c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a32931103c, replyNumber=0, likeNumber=27, createdTime=2021-12-31, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a32931103c, moduleTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a32931103c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528829, encodeId=77a6152882900, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=36, createdTime=2021-12-30, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528828, encodeId=1f1e1528828b6, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=球囊静脉成形术成功治疗难治性颅内静脉窦血栓形成1例报告, objectType=article, longId=292856, objectId=409929285659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=409929285659, replyNumber=0, likeNumber=68, createdTime=2021-12-29, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=409929285659, moduleTitle=球囊静脉成形术成功治疗难治性颅内静脉窦血栓形成1例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=409929285659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528827, encodeId=3b3d152882e31, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？, objectType=article, longId=292206, objectId=f8ff29220653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8ff29220653, replyNumber=0, likeNumber=61, createdTime=2021-12-20, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8ff29220653, moduleTitle=Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8ff29220653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528825, encodeId=702e152882514, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤, objectType=article, longId=292051, objectId=1254292051ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1254292051ee, replyNumber=0, likeNumber=77, createdTime=2021-12-18, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1254292051ee, moduleTitle=Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1254292051ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528826, encodeId=5ee2152882616, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, objectType=article, longId=291974, objectId=52c52919e488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52c52919e488, replyNumber=0, likeNumber=116, createdTime=2021-12-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52c52919e488, moduleTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52c52919e488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528824, encodeId=ab671528824e8, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Neuromodulation:神经刺激治疗难治性慢性腰痛疗效的持久性, objectType=article, longId=291888, objectId=751929188836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751929188836, replyNumber=0, likeNumber=69, createdTime=2021-12-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751929188836, moduleTitle=Neuromodulation:神经刺激治疗难治性慢性腰痛疗效的持久性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=751929188836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528823, encodeId=862b15288236c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=BJH：用美氟芬加地塞米松治疗的复发/难治性多发性骨髓瘤的患者报告结果, objectType=article, longId=264960, objectId=64ea2649609a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ea2649609a, replyNumber=0, likeNumber=95, createdTime=2021-12-12, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ea2649609a, moduleTitle=BJH：用美氟芬加地塞米松治疗的复发/难治性多发性骨髓瘤的患者报告结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64ea2649609a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

THER ADV GASTROENTER：乌司奴单抗对难治性克罗恩病患者的疗效分析

2022-02-28

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病

2022-02-26

freve (审核中...)

前往app查看评论内容

#难治性#

JAK抑制剂「乌帕替尼」在华获批，用于治疗成人和12岁及以上儿童及青少年的难治性、中度至重度特应性皮炎

2022-02-21

freve (审核中...)

前往app查看评论内容

#难治性#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-02-20

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌

2022-02-17

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：泊马度胺-地塞米松方案加用Isatuximab可显著延长复发/难治性多发性骨髓瘤患者的总生存期

2022-02-15

freve (审核中...)

前往app查看评论内容

#难治性#

AJH：使用泊马度胺和地塞米松±皮下达雷妥尤单抗治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量——来自 APOLLO 试验的患者报告结果

2022-02-10

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤

2022-02-08

freve (审核中...)

前往app查看评论内容

#难治性#

Neurology：综合多研究，MRI诊断局灶性皮质发育不良难治性癫痫术后优良预后率达70%

2022-01-18

freve (审核中...)

前往app查看评论内容

#难治性#

Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS

2022-01-18

freve (审核中...)

前往app查看评论内容

#难治性#

J Dermatol：阿普利司特可有效治疗难治性和复发性皮肌炎相关皮损

2022-01-17

freve (审核中...)

前往app查看评论内容

#难治性#

Haematol：达雷妥尤单抗可能用于多发性难治性自身免疫性血细胞减少症

2022-01-05

freve (审核中...)

前往app查看评论内容

#难治性#

STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好

2021-12-31

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2021-12-30

freve (审核中...)

前往app查看评论内容

#难治性#

球囊静脉成形术成功治疗难治性颅内静脉窦血栓形成1例报告

2021-12-29

freve (审核中...)

前往app查看评论内容

#难治性#

Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？

2021-12-20

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：采用CAR T 细胞Axicabtagene ciloleucel治疗复发/难治性惰性非霍奇金淋巴瘤

2021-12-18

一叶知秋 (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性

2021-12-18

freve (审核中...)

前往app查看评论内容

#难治性#

Neuromodulation:神经刺激治疗难治性慢性腰痛疗效的持久性

2021-12-16

freve (审核中...)

前往app查看评论内容

#难治性#

BJH：用美氟芬加地塞米松治疗的复发/难治性多发性骨髓瘤的患者报告结果

2021-12-12

科室
- - 订阅+
  - 更多科室
工具
服务